LVGN6051

BIOLOGICAL2 trials

Sponsors

Lyvgen Biopharma Holdings Limited

Conditions

Cancer

Phase 1

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruitingNCT04130542

Lyvgen Biopharma Holdings LimitedCancer

Start: 2019-10-31End: 2025-12-31Target: 276Updated: 2024-10-31

Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

CompletedNCT04694781

Lyvgen Biopharma Holdings LimitedCancer

Start: 2021-05-14End: 2023-10-31Updated: 2024-04-19

Related Papers

Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.

Journal of Clinical Oncology2024-06-01

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-012 citations

Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.

Journal of Clinical Oncology2021-05-207 citations